P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE

Introduction. Minimal residual disease (MRD) negativity and sustained MRD negativity are associated with longer survival and are strong prognostic clinical endpoints. PERSEUS (NCT03710603) evaluated subcutaneous Dara + VRd induction/consolidation + DR maintenance vs VRd induction/consolidation + R...

Celý popis

Podrobná bibliografie

Hlavní autoři:	P. Sonneveld, Ph. Moreau, H. Einsele, H. Quach, P.J. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, H. Pei, A. Sitthi-Amorn, R.L. Carson, P. Rodríguez-Otero, M.A. Dimopoulos, M. Boccadoro
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Ferrata Storti Foundation 2026-04-01
Edice:	Haematologica
On-line přístup:	https://haematologica.org/article/view/14037
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!